tetano
Editor, Senior Moderator
Lancet
. 2022 Jun 11;399(10342):2212-2225.
doi: 10.1016/S0140-6736(22)00770-X.
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial
Grace Li[SUP] 1 [/SUP], Federica Cappuccini[SUP] 2 [/SUP], Natalie G Marchevsky[SUP] 1 [/SUP], Parvinder K Aley[SUP] 1 [/SUP], Robert Aley[SUP] 1 [/SUP], Rachel Anslow[SUP] 1 [/SUP], Sagida Bibi[SUP] 1 [/SUP], Katrina Cathie[SUP] 3 [/SUP], Elizabeth Clutterbuck[SUP] 1 [/SUP], Saul N Faust[SUP] 3 [/SUP], Shuo Feng[SUP] 1 [/SUP], Paul T Heath[SUP] 4 [/SUP], Simon Kerridge[SUP] 1 [/SUP], Alice Lelliott[SUP] 1 [/SUP], Yama Mujadidi[SUP] 1 [/SUP], Khuen Foong Ng[SUP] 5 [/SUP], Sarah Rhead[SUP] 1 [/SUP], Hannah Roberts[SUP] 1 [/SUP], Hannah Robinson[SUP] 1 [/SUP], Marion R Roderick[SUP] 5 [/SUP], Nisha Singh[SUP] 1 [/SUP], David Smith[SUP] 1 [/SUP], Matthew D Snape[SUP] 1 [/SUP], Rinn Song[SUP] 1 [/SUP], Karly Tang[SUP] 1 [/SUP], Andy Yao[SUP] 1 [/SUP], Xinxue Liu[SUP] 6 [/SUP], Teresa Lambe[SUP] 7 [/SUP], Andrew J Pollard[SUP] 8 [/SUP], COV006 study team
Collaborators, Affiliations
Abstract
Background: Vaccination of children and young people against SARS-CoV-2 is recommended in some countries. Scarce data have been published on immune responses induced by COVID-19 vaccines in people younger than 18 years compared with the same data that are available in adults.
Methods: COV006 is a phase 2, single-blind, randomised, controlled trial of ChAdOx1 nCoV-19 (AZD1222) in children and adolescents at four trial sites in the UK. Healthy participants aged 6-17 years, who did not have a history of chronic respiratory conditions, laboratory-confirmed COVID-19, or previously received capsular group B meningococcal vaccine (the control), were randomly assigned to four groups (4:1:4:1) to receive two intramuscular doses of 5 × 10[SUP]10[/SUP] viral particles of ChAdOx1 nCoV-19 or control, 28 days or 84 days apart. Participants, clinical investigators, and the laboratory team were masked to treatment allocation. Study groups were stratified by age, and participants aged 12-17 years were enrolled before those aged 6-11 years. Due to the restrictions in the use of ChAdOx1 nCoV-19 in people younger than 30 years that were introduced during the study, only participants aged 12-17 years who were randomly assigned to the 28-day interval group had received their vaccinations at the intended interval (day 28). The remaining participants received their second dose at day 112. The primary outcome was assessment of safety and tolerability in the safety population, which included all participants who received at least one dose of the study drug. The secondary outcome was immunogenicity, which was assessed in participants who were seronegative to the nucleocapsid protein at baseline and received both prime and boost vaccine. This study is registered with ISRCTN (15638344).
Findings: Between Feb 15 and April 2, 2021, 262 participants (150 [57%] participants aged 12-17 years and 112 [43%] aged 6-11 years; due to the change in the UK vaccination policy, the study terminated recruitment of the younger age group before the planned number of participants had been enrolled) were randomly assigned to receive vaccination with two doses of either ChAdOx1 nCoV-19 (n=211 [n=105 at day 28 and n=106 at day 84]) or control (n=51 [n=26 at day 28 and n=25 at day 84]). One participant in the ChAdOx1 nCoV-19 day 28 group in the younger age bracket withdrew their consent before receiving a first dose. Of the participants who received ChAdOx1 nCoV-19, 169 (80%) of 210 participants reported at least one solicited local or systemic adverse event up to 7 days following the first dose, and 146 (76%) of 193 participants following the second dose. No serious adverse events related to ChAdOx1 nCoV-19 administration were recorded by the data cutoff date on Oct 28, 2021. Of the participants who received at least one dose of ChAdOx1 nCoV-19, there were 128 unsolicited adverse events up to 28 days after vaccination reported by 83 (40%) of 210 participants. One participant aged 6-11 years receiving ChAdOx1 nCoV-19 reported a grade 4 fever of 40·2°C on day 1 following first vaccination, which resolved within 24 h. Pain and tenderness were the most common local solicited adverse events for all the ChAdOx1 nCoV-19 and capsular group B meningococcal groups following both doses. Of the 242 participants with available serostatus data, 14 (6%) were seropositive at baseline. Serostatus data were not available for 20 (8%) of 262 participants. Among seronegative participants who received ChAdOx1 nCoV-19, anti-SARS-CoV-2 IgG and pseudoneutralising antibody titres at day 28 after the second dose were higher in participants aged 12-17 years with a longer interval between doses (geometric means of 73 371 arbitrary units [AU]/mL [95% CI 58 685-91 733] and 299 half-maximal inhibitory concentration [IC[SUB]50[/SUB]; 95% CI 230-390]) compared with those aged 12-17 years who received their vaccines 28 days apart (43 280 AU/mL [95% CI 35 852-52 246] and 150 IC[SUB]50[/SUB] [95% CI 116-194]). Humoral responses were higher in those aged 6-11 years than in those aged 12-17 years receiving their second dose at the same 112-day interval (geometric mean ratios 1·48 [95% CI 1·07-2·07] for anti-SARS-CoV-2 IgG and 2·96 [1·89-4·62] for pseudoneutralising antibody titres). Cellular responses peaked after a first dose of ChAdOx1 nCoV-19 across all age and interval groups and remained above baseline after a second vaccination.
Interpretation: ChAdOx1 nCoV-19 is well tolerated and immunogenic in children aged 6-17 years, inducing concentrations of antibody that are similar to those associated with high efficacy in phase 3 studies in adults. No safety concerns were raised in this trial.
Funding: AstraZeneca and the UK Department of Health and Social Care through the UK National Institute for Health and Care Research.
. 2022 Jun 11;399(10342):2212-2225.
doi: 10.1016/S0140-6736(22)00770-X.
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial
Grace Li[SUP] 1 [/SUP], Federica Cappuccini[SUP] 2 [/SUP], Natalie G Marchevsky[SUP] 1 [/SUP], Parvinder K Aley[SUP] 1 [/SUP], Robert Aley[SUP] 1 [/SUP], Rachel Anslow[SUP] 1 [/SUP], Sagida Bibi[SUP] 1 [/SUP], Katrina Cathie[SUP] 3 [/SUP], Elizabeth Clutterbuck[SUP] 1 [/SUP], Saul N Faust[SUP] 3 [/SUP], Shuo Feng[SUP] 1 [/SUP], Paul T Heath[SUP] 4 [/SUP], Simon Kerridge[SUP] 1 [/SUP], Alice Lelliott[SUP] 1 [/SUP], Yama Mujadidi[SUP] 1 [/SUP], Khuen Foong Ng[SUP] 5 [/SUP], Sarah Rhead[SUP] 1 [/SUP], Hannah Roberts[SUP] 1 [/SUP], Hannah Robinson[SUP] 1 [/SUP], Marion R Roderick[SUP] 5 [/SUP], Nisha Singh[SUP] 1 [/SUP], David Smith[SUP] 1 [/SUP], Matthew D Snape[SUP] 1 [/SUP], Rinn Song[SUP] 1 [/SUP], Karly Tang[SUP] 1 [/SUP], Andy Yao[SUP] 1 [/SUP], Xinxue Liu[SUP] 6 [/SUP], Teresa Lambe[SUP] 7 [/SUP], Andrew J Pollard[SUP] 8 [/SUP], COV006 study team
Collaborators, Affiliations
- PMID: 35691324
- DOI: 10.1016/S0140-6736(22)00770-X
Abstract
Background: Vaccination of children and young people against SARS-CoV-2 is recommended in some countries. Scarce data have been published on immune responses induced by COVID-19 vaccines in people younger than 18 years compared with the same data that are available in adults.
Methods: COV006 is a phase 2, single-blind, randomised, controlled trial of ChAdOx1 nCoV-19 (AZD1222) in children and adolescents at four trial sites in the UK. Healthy participants aged 6-17 years, who did not have a history of chronic respiratory conditions, laboratory-confirmed COVID-19, or previously received capsular group B meningococcal vaccine (the control), were randomly assigned to four groups (4:1:4:1) to receive two intramuscular doses of 5 × 10[SUP]10[/SUP] viral particles of ChAdOx1 nCoV-19 or control, 28 days or 84 days apart. Participants, clinical investigators, and the laboratory team were masked to treatment allocation. Study groups were stratified by age, and participants aged 12-17 years were enrolled before those aged 6-11 years. Due to the restrictions in the use of ChAdOx1 nCoV-19 in people younger than 30 years that were introduced during the study, only participants aged 12-17 years who were randomly assigned to the 28-day interval group had received their vaccinations at the intended interval (day 28). The remaining participants received their second dose at day 112. The primary outcome was assessment of safety and tolerability in the safety population, which included all participants who received at least one dose of the study drug. The secondary outcome was immunogenicity, which was assessed in participants who were seronegative to the nucleocapsid protein at baseline and received both prime and boost vaccine. This study is registered with ISRCTN (15638344).
Findings: Between Feb 15 and April 2, 2021, 262 participants (150 [57%] participants aged 12-17 years and 112 [43%] aged 6-11 years; due to the change in the UK vaccination policy, the study terminated recruitment of the younger age group before the planned number of participants had been enrolled) were randomly assigned to receive vaccination with two doses of either ChAdOx1 nCoV-19 (n=211 [n=105 at day 28 and n=106 at day 84]) or control (n=51 [n=26 at day 28 and n=25 at day 84]). One participant in the ChAdOx1 nCoV-19 day 28 group in the younger age bracket withdrew their consent before receiving a first dose. Of the participants who received ChAdOx1 nCoV-19, 169 (80%) of 210 participants reported at least one solicited local or systemic adverse event up to 7 days following the first dose, and 146 (76%) of 193 participants following the second dose. No serious adverse events related to ChAdOx1 nCoV-19 administration were recorded by the data cutoff date on Oct 28, 2021. Of the participants who received at least one dose of ChAdOx1 nCoV-19, there were 128 unsolicited adverse events up to 28 days after vaccination reported by 83 (40%) of 210 participants. One participant aged 6-11 years receiving ChAdOx1 nCoV-19 reported a grade 4 fever of 40·2°C on day 1 following first vaccination, which resolved within 24 h. Pain and tenderness were the most common local solicited adverse events for all the ChAdOx1 nCoV-19 and capsular group B meningococcal groups following both doses. Of the 242 participants with available serostatus data, 14 (6%) were seropositive at baseline. Serostatus data were not available for 20 (8%) of 262 participants. Among seronegative participants who received ChAdOx1 nCoV-19, anti-SARS-CoV-2 IgG and pseudoneutralising antibody titres at day 28 after the second dose were higher in participants aged 12-17 years with a longer interval between doses (geometric means of 73 371 arbitrary units [AU]/mL [95% CI 58 685-91 733] and 299 half-maximal inhibitory concentration [IC[SUB]50[/SUB]; 95% CI 230-390]) compared with those aged 12-17 years who received their vaccines 28 days apart (43 280 AU/mL [95% CI 35 852-52 246] and 150 IC[SUB]50[/SUB] [95% CI 116-194]). Humoral responses were higher in those aged 6-11 years than in those aged 12-17 years receiving their second dose at the same 112-day interval (geometric mean ratios 1·48 [95% CI 1·07-2·07] for anti-SARS-CoV-2 IgG and 2·96 [1·89-4·62] for pseudoneutralising antibody titres). Cellular responses peaked after a first dose of ChAdOx1 nCoV-19 across all age and interval groups and remained above baseline after a second vaccination.
Interpretation: ChAdOx1 nCoV-19 is well tolerated and immunogenic in children aged 6-17 years, inducing concentrations of antibody that are similar to those associated with high efficacy in phase 3 studies in adults. No safety concerns were raised in this trial.
Funding: AstraZeneca and the UK Department of Health and Social Care through the UK National Institute for Health and Care Research.